Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Severe COVID-19
NCT04404361Phase 2Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in coronavirus disease 2019 (COVID-19), sponsored by CTI BioPharma Corp.. Started May 2020; status: terminated.
02
Drugs
pacritinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04404361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404361.